Your browser is no longer supported. Please, upgrade your browser.
Settings
ZIOP ZIOPHARM Oncology, Inc. daily Stock Chart
ZIOP [NASD]
ZIOPHARM Oncology, Inc.
Index- P/E4.50 EPS (ttm)0.98 Insider Own0.30% Shs Outstand156.51M Perf Week2.69%
Market Cap687.08M Forward P/E- EPS next Y-0.32 Insider Trans0.00% Shs Float156.51M Perf Month9.34%
Income147.80M PEG- EPS next Q-0.09 Inst Own49.50% Short Float32.28% Perf Quarter-13.24%
Sales0.00M P/S- EPS this Y278.50% Inst Trans-0.38% Short Ratio33.25 Perf Half Y0.00%
Book/sh0.39 P/B11.40 EPS next Y8.60% ROA100.10% Target Price6.29 Perf Year62.59%
Cash/sh0.56 P/C7.77 EPS next 5Y- ROE112.80% 52W Range1.56 - 7.25 Perf YTD134.76%
Dividend- P/FCF- EPS past 5Y28.00% ROI-63.00% 52W High-39.45% Beta2.52
Dividend %- Quick Ratio10.30 Sales past 5Y-28.80% Gross Margin- 52W Low181.41% ATR0.27
Employees48 Current Ratio10.30 Sales Q/Q- Oper. Margin- RSI (14)52.08 Volatility8.49% 6.40%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.70 Prev Close4.55
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout0.00% Avg Volume1.52M Price4.39
Recom2.50 SMA203.55% SMA501.42% SMA200-1.19% Volume1,081,260 Change-3.52%
Aug-23-19Resumed Raymond James Outperform
Apr-04-19Initiated Lake Street Buy $7
Apr-01-19Initiated Laidlaw Buy $7.50
Nov-15-18Upgrade Raymond James Mkt Perform → Outperform
Jun-18-18Downgrade JP Morgan Neutral → Underweight
Jun-01-17Initiated H.C. Wainwright Buy $9.50
Aug-10-16Upgrade Wells Fargo Underperform → Market Perform
Jul-19-16Reiterated Mizuho Neutral $7 → $5
Jun-02-16Initiated Raymond James Mkt Perform
May-11-16Reiterated Mizuho Neutral $6 → $7
Jan-25-16Reiterated Mizuho Neutral $10 → $6
Dec-04-15Initiated Wells Fargo Underperform
Jun-10-15Reiterated Mizuho Neutral $14 → $10
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-02-15Reiterated Mizuho Buy $11 → $14
Mar-20-14Initiated Mizuho Buy $11
Apr-02-12Reiterated Griffin Securities Buy $9 → $12
Mar-26-12Initiated Canaccord Genuity Buy $9
Dec-15-11Initiated Global Hunter Securities Buy $9
Nov-22-11Initiated Collins Stewart Buy $9
Nov-11-19 09:10AM  Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast GlobeNewswire -5.41%
Nov-08-19 02:44AM  Edited Transcript of ZIOP earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-19 04:05PM  Ziopharm Oncology Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-30-19 08:30AM  Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019 GlobeNewswire
Oct-28-19 06:06PM  Hedge Funds Have Never Been More Bullish On ZIOPHARM Oncology Inc. (ZIOP) Insider Monkey
08:00AM  Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program GlobeNewswire
Oct-18-19 06:00AM  Ziopharm Tests "Sleeping Beauty" for Oncology Treatment MoneyShow
Oct-15-19 08:00AM  Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors GlobeNewswire
Oct-11-19 12:49PM  Jazz Starts CAR T-cell Linked Neurotoxicity Study Enrollment Zacks
Oct-01-19 08:00AM  Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T GlobeNewswire
Sep-30-19 06:45AM  MDNA.TO: Increased Overall Survival in rGBM Patients Seen with High Dose MDNA55 Zacks Small Cap Research
Sep-03-19 02:21PM  In expense-laden biotech industry, here are the Mass. startups most in need of cash American City Business Journals -5.01%
Aug-28-19 04:05PM  Ziopharm Oncology to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference GlobeNewswire +5.23%
Aug-23-19 07:00AM  Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -6.61%
Aug-16-19 01:40AM  Edited Transcript of ZIOP earnings conference call or presentation 8-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-14-19 02:00PM  Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine GlobeNewswire
Aug-09-19 02:11PM  ZIOPHARM Oncology, Inc. (ZIOP) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 07:50AM  Ziopharm Oncology Reports Second Quarter 2019 Financial Results GlobeNewswire -8.68%
07:40AM  Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma GlobeNewswire
Jul-30-19 09:15AM  Ziopharm Oncology to Host Conference Call to Discuss Second Quarter 2019 Results on August 8, 2019 GlobeNewswire +9.85%
Jul-29-19 08:40AM  Ziopharm Oncology Announces $45 Million Warrant Exercise by Existing Shareholders in a Private Placement GlobeNewswire
Jul-25-19 06:00AM  Ziopharm Attracts Top Talent from the National Cancer Institute MoneyShow
Jul-24-19 08:30AM  Ziopharm Oncology Names Sath Shukla as Chief Financial Officer GlobeNewswire
Jul-03-19 08:30AM  Ziopharm Oncology Names NCIs Dr. Drew Deniger to Direct TCR-T Cell Therapy Program GlobeNewswire +10.87%
Jun-27-19 04:10PM  Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo® (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma GlobeNewswire
Jun-26-19 08:30AM  Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo® (nivolumab) Phase 1 Combination Trial in Brain Cancer GlobeNewswire
Jun-17-19 01:05PM  ZIOPHARM Oncology (NASDAQ:ZIOP) Shareholders Have Enjoyed A 21% Share Price Gain Simply Wall St. +9.58%
08:30AM  Ziopharm Oncology Appoints Heidi Hagen to Board of Directors GlobeNewswire
Jun-11-19 08:00AM  Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI GlobeNewswire +5.48%
Jun-02-19 09:10AM  Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting GlobeNewswire
May-29-19 07:38AM  The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation Benzinga
May-28-19 04:10PM  Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty Platform GlobeNewswire
May-23-19 04:15PM  Ziopharm Oncology Presentation at the Jefferies 2019 Global Healthcare Conference to be Webcast GlobeNewswire
May-17-19 07:21PM  Edited Transcript of ZIOP earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 05:19PM  Ziopharm: 1Q Earnings Snapshot Associated Press
04:03PM  Ziopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines GlobeNewswire
02:30PM  ZIOPHARM Oncology, Inc. to Host Earnings Call ACCESSWIRE
May-01-19 04:10PM  Ziopharm Oncology to Host Conference Call to Discuss First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-25-19 02:45AM  Edited Transcript of ZIOP earnings conference call or presentation 5-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
Apr-16-19 03:08PM  What Kind Of Shareholder Appears On The ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Shareholder Register? Simply Wall St. +5.21%
Apr-01-19 10:36AM  Ziopharma's Lead Asset Snags Fast Track Designation For Cancer Treatment Benzinga
07:00AM  Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma GlobeNewswire
Mar-05-19 07:00PM  Ziopharm Oncology Inc (ZIOP) Q4 2018 Earnings Conference Call Transcript Motley Fool +8.86%
04:01PM  Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-01-19 09:16AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4 Zacks
Feb-25-19 07:50AM  Ziopharm Oncology to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 5 GlobeNewswire
Feb-21-19 08:30AM  Ziopharm Oncology CEO to Present at the CAR-TCR Summit Europe GlobeNewswire
Feb-14-19 08:30AM  Recent Analysis Shows Lattice Semiconductor, ZIOPHARM Oncology, Ferro, SYNNEX, AxoGen, and Twin Disc Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-13-19 06:49AM  Is ZIOPHARM Oncology, Inc.s (NASDAQ:ZIOP) CEO Paid At A Competitive Rate? Simply Wall St.
Feb-11-19 07:45AM  Ziopharm Oncology Completes Enrollment of Controlled IL-12 Monotherapy Expansion Substudy in Phase 1 Brain Cancer Trial GlobeNewswire
Feb-01-19 07:30AM  The Unknown Biotech Play that Could Deliver 400% Returns, or Much More ACCESSWIRE
Jan-21-19 09:00AM  Biotech Stocks on the Move ACCESSWIRE
Jan-07-19 04:01PM  Ziopharm Oncology Posts Letter to Stockholders GlobeNewswire
Dec-28-18 08:52AM  Ziopharm Oncology (ZIOP) in Focus: Stock Moves 6.2% Higher Zacks
Dec-27-18 01:16PM  Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets GlobeNewswire +6.21%
12:45PM  4 Healthcare Stocks That Could Test December Highs ACCESSWIRE
Dec-23-18 09:26PM  Do Hedge Funds Love ZIOPHARM Oncology Inc. (ZIOP)? Insider Monkey
Dec-21-18 09:15AM  Is the Options Market Predicting a Spike in Ziopharm Oncology (ZIOP) Stock? Zacks -7.44%
08:00AM  Ziopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-18 06:59AM  Ziopharm Oncology and TriArm Therapeutics Establish Joint Venture to Develop and Commercialize Sleeping Beauty CAR T in China, Taiwan and Korea GlobeNewswire -5.35%
Dec-14-18 07:47AM  The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch Benzinga
Dec-13-18 04:15PM  Ziopharm Oncology Promotes Dr. David Mauney to President GlobeNewswire
Dec-04-18 08:17PM  Edited Transcript of ZIOP earnings conference call or presentation 12-Nov-18 1:00pm GMT Thomson Reuters StreetEvents -5.69%
Dec-03-18 07:25AM  Market Trends Toward New Normal in Zillow Group, YRC Worldwide, The Home Depot, UROGEN PHARMA, ZIOPHARM Oncology, and Cinedigm Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-29-18 08:40AM  Are Options Traders Betting on a Big Move in ZIOPHARM Oncology (ZIOP) Stock? Zacks -9.12%
Nov-16-18 02:30PM  Ziopharm Oncology Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented at Annual Meeting of the Society for Neuro-Oncology GlobeNewswire
08:08AM  The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal Benzinga
Nov-14-18 09:15AM  Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges Zacks
Nov-13-18 02:10PM  Ziopharm Oncology (ZIOP) Reports Q3 Loss, Lags Revenue Estimates Zacks +16.38%
Nov-12-18 07:01AM  Ziopharm Oncology to Host Conference Call Today at 8 a.m. GlobeNewswire -7.57%
07:00AM  Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer GlobeNewswire
06:58AM  Ziopharm Oncology Announces $50 Million Private Placement GlobeNewswire
Nov-11-18 10:01AM  Is ZIOPHARM Oncology Inc (NASDAQ:ZIOP) A Financially Sound Company? Simply Wall St.
Nov-09-18 02:08PM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3 Zacks
Nov-08-18 04:01PM  Ziopharm Oncology Third Quarter 2018 Financial Results Conference Call Rescheduled to Nov. 12 GlobeNewswire
Nov-07-18 04:02PM  Ziopharm Oncology to Present at the Stifel 2018 Healthcare Conference on Nov. 14 GlobeNewswire +8.33%
Nov-05-18 07:00AM  Ziopharm Oncology to Present Update on Controlled IL-12 Brain Cancer Trial at Annual Meeting of the Society for Neuro-Oncology on Nov. 16 GlobeNewswire
Oct-31-18 04:30PM  Ziopharm Oncology to Announce Third Quarter 2018 Financial Results, Host Conference Call Nov. 8 GlobeNewswire
Oct-29-18 10:31AM  Ziopharm Oncology (ZIOP) Q3 Earnings Preview: What's Shaping Up? Zacks -8.37%
Oct-26-18 08:49AM  Implied Volatility Surging for ZIOPHARM Oncology (ZIOP) Stock Options Zacks
Oct-24-18 07:25AM  Report: Developing Opportunities within Univar, Aqua America, Chimerix, Superior Energy Services, TechTarget, and ZIOPHARM Oncology Future Expectations, Projections Moving into 2018 GlobeNewswire -6.82%
Oct-16-18 04:01PM  Ziopharm Oncology Announces Changes to Board of Directors and Management Team GlobeNewswire +8.47%
Oct-09-18 07:00AM  Ziopharm and Precigen Redefine Relationships, Announce New License Agreement GlobeNewswire
Sep-25-18 07:30AM  Ziopharm Oncology to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-20-18 08:36AM  Should You Have ZIOPHARM Oncology Incs (NASDAQ:ZIOP) In Your Portfolio? Simply Wall St. +7.02%
Sep-19-18 08:55AM  Is the Options Market Predicting a Spike in ZIOPHARM Oncology (ZIOP) Stock? Zacks
Sep-04-18 09:15AM  CORRECTING and REPLACING -- Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors GlobeNewswire
07:30AM  Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors GlobeNewswire
Aug-22-18 07:50PM  Edited Transcript of ZIOP earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents -7.33%
Aug-14-18 07:57AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Ziopharm Oncology, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire -5.90%
Aug-11-18 07:03AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Aug-09-18 03:36PM  Why Ziopharm Oncology Is Soaring 14% Today Motley Fool +10.76%
Aug-08-18 07:35PM  Ziopharm Oncology (ZIOP) Reports Q2 Loss, Lags Revenue Estimates Zacks -5.64%
06:32PM  Ziopharm: 2Q Earnings Snapshot Associated Press
04:01PM  Ziopharm Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  ZIOPHARM Oncology, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-18 04:00PM  Why Ziopharm Oncology Stock Zoomed 16.8% Higher Today Motley Fool +17.70%
07:30AM  Ziopharm Oncology Announces Changes to its Board of Directors GlobeNewswire
Jul-31-18 07:45AM  Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8 GlobeNewswire +6.15%
Jul-30-18 07:20AM  Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks ACCESSWIRE
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. Its lead gene therapy product candidate is Ad-RTS-hIL-12 plus veledimex, which is in Phase I clinical trial, to treat patients with recurrent glioblastoma and breast cancer. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; research and development agreement with the National Cancer Institute, and Ares Trading S.A. The company is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CANNON JAMES ANTHONYDirectorMay 07Option Exercise0.7015,00010,500398,050May 08 04:37 PM